These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35063966)

  • 1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.
    Guerrero C; Puig N; Cedena MT; Goicoechea I; Perez C; Garcés JJ; Botta C; Calasanz MJ; Gutierrez NC; Martin-Ramos ML; Oriol A; Rios R; Hernandez MT; Martinez-Martinez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Mosquera-Orgueira A; Gonzalez-Perez MS; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B
    Clin Cancer Res; 2022 Jun; 28(12):2598-2609. PubMed ID: 35063966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
    Guerrero C; Puig N; Cedena MT; Calasanz MJ; Gutierrez NC; Fernandez M; Oriol A; Ríos-Tamayo R; Hernandez MT; Martínez-Martínez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Gonzalez Perez MS; Orfao A; Mateos MV; Martinez-Lopez J; Rosiñol L; Bladé J; Lahuerta JJ; San-Miguel JF; Paiva B
    Blood; 2024 Feb; 143(7):597-603. PubMed ID: 38048552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
    Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
    J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
    Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G
    Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the Future: Machine-Based Learning for MRD Prognostication.
    Pawlyn C; Davies FE
    Clin Cancer Res; 2022 Jun; 28(12):2482-2484. PubMed ID: 35357437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
    Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
    Garcés JJ; Cedena MT; Puig N; Burgos L; Perez JJ; Cordon L; Flores-Montero J; Sanoja-Flores L; Calasanz MJ; Ortiol A; Blanchard MJ; Rios R; Martin J; Martínez-Martinez R; Bargay J; Sureda A; de la Rubia J; Hernandez MT; Rodriguez-Otero P; de la Cruz J; Orfao A; Mateos MV; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; San-Miguel JF; Paiva B
    J Clin Oncol; 2022 Sep; 40(27):3151-3161. PubMed ID: 35666958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
    Paiva B; Cedena MT; Puig N; Arana P; Vidriales MB; Cordon L; Flores-Montero J; Gutierrez NC; Martín-Ramos ML; Martinez-Lopez J; Ocio EM; Hernandez MT; Teruel AI; Rosiñol L; Echeveste MA; Martinez R; Gironella M; Oriol A; Cabrera C; Martin J; Bargay J; Encinas C; Gonzalez Y; Van Dongen JJ; Orfao A; Bladé J; Mateos MV; Lahuerta JJ; San Miguel JF;
    Blood; 2016 Jun; 127(25):3165-74. PubMed ID: 27118453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
    Lakhwani S; Rosiñol L; Puig N; Pico-Picos MA; Medina-González L; Martínez-López J; Paiva B; Cedena MT; Oriol A; Ríos-Tamayo R; Blanchard MJ; Jarque I; Bargay J; Moraleda JM; Carrillo-Cruz E; Sureda A; Krsnik I; González E; Casado LF; Martí JM; Encinas C; De Arriba F; Palomera L; Sampol A; González-Montes Y; Motlló C; De La Cruz J; Alonso R; Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J; Hernández MT
    Haematologica; 2024 Jun; 109(6):1909-1917. PubMed ID: 38031761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
    Landgren O; Devlin S; Boulad M; Mailankody S
    Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
    Goicoechea I; Puig N; Cedena MT; Burgos L; Cordón L; Vidriales MB; Flores-Montero J; Gutierrez NC; Calasanz MJ; Ramos MM; Lara-Astiaso D; Vilas-Zornoza A; Alignani D; Rodriguez I; Sarvide S; Alameda D; Garcés JJ; Rodriguez S; Fresquet V; Celay J; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Rios R; Martin-Sanchez J; Martinez-Martinez R; Sarra J; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Martinez-Climent JA; Orfao A; Rosiñol L; Mateos MV; Lahuerta JJ; Blade J; San Miguel J; Paiva B
    Blood; 2021 Jan; 137(1):49-60. PubMed ID: 32693406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool.
    Landgren O
    Semin Hematol; 2018 Jan; 55(1):1-3. PubMed ID: 29759146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
    Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is molecular remission the goal of multiple myeloma therapy?
    Davies FE
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):205-211. PubMed ID: 29222257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal genetically detectable minimal residual disease by fluorescence
    Cui J; Yu T; Lv R; Liu J; Fan H; Yan W; Xu J; Du C; Deng S; Sui W; Ho M; Xu Y; Anderson KC; Dong X; Qiu L; An G
    Ther Adv Med Oncol; 2024; 16():17588359231221340. PubMed ID: 38249329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.
    Landgren O; Prior TJ; Masterson T; Heuck C; Bueno OF; Dash AB; Einsele H; Goldschmidt H; Knop S; Li C; Mellqvist UH; McFadden I; Oprea C; Ross JA; Talpes M; Hydren JR; Ahlstrom JM; Kazandjian D; Weinhold N; Zhang R; Stetler-Stevenson M; Marti G; Devlin SM
    Blood; 2024 Jul; 144(4):359-367. PubMed ID: 38768337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.